Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study

Clinical Snapshot

Key Findings

• P Value: p=0.0007

• Effect Size: 30% relative risk reduction in disability progression

• Primary Outcome: 12-week composite confirmed disability progression in 9-Hole Peg Test or EDSS

• Nnt Or Sensitivity: NNT approximately 14 patients (based on 7% absolute risk reduction: 40% vs 33%)

• Confidence Interval: 95% CI 0.57-0.86

Clinical Application

Requires specialised MS centres with infusion facilities and regular monitoring capabilities Ocrelizumab is PBS-listed for PPMS in Australia; study supports use in broader patient population than original ORATORIO trial, potentially informing PBAC considerations for expanded access Australian patients with PPMS aged 18-65 years with EDSS 3.0-8.0, particularly those with more advanced disease or older age

Abstract

BACKGROUND: The ORATORIO trial showed that ocrelizumab reduced the risk of disability progression versus placebo in patients with primary progressive multiple sclerosis (PPMS). We aimed to elucidate the effect of ocrelizumab in older and more disabled patients with PPMS, particularly regarding hand function preservation. METHODS: ORATORIO-HAND was a multicentre, double-blind, randomised, placebo-controlled, phase 3b study with 138 sites across 22 countries. Patients with PPMS aged 18-65 years and Expanded Disability Status Scale (EDSS) score of 3·0-8·0 were randomly assigned 1:1 to intravenous ocrelizumab 600 mg or placebo every 6 months for 144 weeks or until a prespecified number of progression events occurred. Masking was achieved by use of a placebo solution administered in the same manner as ocrelizumab. Double-blinding across all periods was maintained through separation of investigators responsible for efficacy and safety assessments. MRI scans were evaluated by a masked central reader, and laboratory parameters that could reveal treatment allocation were masked to site personnel until the primary analysis. Two coprimary estimands were defined, with the endpoint of time to onset of 12-week composite confirmed disability progression (12W-cCDP) in 9-Hole Peg Test or EDSS evaluated in all randomly assigned patients, and the same endpoint evaluated in a subset of patients with MRI activity at baseline. This study is registered with ClinicalTrials.gov, NCT04035005 and is ongoing and not recruiting. FINDINGS: Between Aug 12, 2019, and Dec 10, 2024, of 1360 patients assessed for eligibility, 1013 were randomly assigned (ocrelizumab [n=505]; placebo [n=508]). The proportion of patients with 12W-cCDP was 165 (33%) of 505 with ocrelizumab and 205 (40%) of 508 with placebo (hazard ratio, 95% CI 0·70 0·57-0·86; relative risk reduction=30%; p=0·0007). In the MRI-active subgroup, a significant risk reduction was also observed in 12W-cCDP (risk reduction=55%; p<0·0001). The overall safety profile was similar in both groups. More infections (245 [48%] of 506 vs 226 [45%] of 506) were observed with ocrelizumab, but not after COVID-19 was excluded (38% vs 37%). Rates of serious adverse events and serious infections were similar between groups. INTERPRETATION: Ocrelizumab was superior to placebo in delaying disability progression, with stronger effect on hand function, in a broad PPMS population including older patients and those with more advanced disease, while maintaining a manageable safety profile. FUNDING: F Hoffmann-La Roche.

References

1. 1.Giovannoni, G., Airas, L., Bove, R., Cutter, G. R., Czarnecki, M., Drulovic, J., Hobart, J., Kuhle, J., Montalban, X., Selmaj, K. W., Tur, C., Wolinsky, J. S., Baldinotti, A., Bonati, U., Craveiro, L., Giacobino, C., Manfrini, M., Schneble, H. M., Stevenson, P., Wang, Q., Yang, K., & Oh, J. (2026). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. *Lancet*, advance online publication. https://doi.org/10.1016/S0140-6736(26)00617-3